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This is the fourth in a series of articles highlighting the delivery of
‘‘packages of care’’ for mental health disorders in low- and middle-
income countries. Packages of care are combinations of treatments aimed
at improving the recognition and management of conditions to achieve
optimal outcomes.
Introduction
Alcohol misuse is responsible for a disproportionately high
health burden, accounting for almost 5% of all ill health and
premature death worldwide in 2004. The impact of alcohol misuse
is worst among poor populations and in low- and middle-income
countries (LMICs) where the disease burden per liter of alcohol
consumed is greater than in wealthy populations. In 2004, the
western Pacific region, Southeast Asia, and the Americas had the
highest prevalence of alcohol use disorders (AUDs) relative to the
average volumes of alcohol consumed. Alcohol attributable net
disability adjusted life years (DALYs) were 13,406, 7,343, and
3,392 in China, India, and Brazil, respectively, and 594 and 393 in
Germany and Japan, respectively, in the same year [1–7].
Sustained, heavy alcohol exposure leads to a chronic relapsing
illness with a characteristic syndromal presentation termed
‘‘dependence.’’ However, alcohol misuse can produce harm
without the presence of dependence. The terms ‘‘hazardous
drinking’’ and ‘‘harmful drinking’’ describe patterns of use likely to
result in or having resulted in physical/psychological harm,
respectively, without satisfying the International Classification of
Disease (ICD) ten criteria for alcohol dependence (Box 1) [8,9].
Most alcohol-related harm is attributable to hazardous/harmful
drinkers rather than to people with alcohol dependence [10–12].
However, this distinction is rarely made, especially in LMICs
where politicians, planners, and the public discourse have focused
primarily on alcohol dependence—the conventional central motif
of alcohol misuse. Concentrating on the rarer presentation of
dependence only serves to minimize the problem, stigmatize the
condition, and marginalize affected individuals.
Studies of alcohol treatment systems across countries show that
the size, extent, and character of the treatment system each
country adopts depends more on its view of the importance of
alcohol problems (and its reliance on alcohol excise) than on actual
changes in alcohol consumption achieved by the system, the need
for treatment in the country, or the economic resources available
for treatment [13]. Furthermore, recent reviews of the current
situation in LMICs indicate that service systems for the treatment
of AUDs, where available, are mainly oriented to tertiary
treatment of dependence with an emphasis on long-term
residential treatment in rehabilitation centres, specialised clinics,
or psychiatric hospitals [14–16]. These facilities are mainly
concentrated in urban areas and are often in private settings,
usually with high fee structures. Where government-funded
treatment/counseling centers are available, the overall efficacy of
these programmes is low [17]. Consequently, many people with
AUDs in LMICs remain untreated (the median treatment gap for
AUDs in LMICs is 78.1%) because they first seek help for early
alcohol-related problems from primary health care providers who
are not trained to recognise the problem [18–20]. Those who are
finally treated often have to wait for over a decade before receiving
treatment for their alcohol misuse [21]. Thus, in many LMICs,
alcohol-related problems are first addressed when they are already
severe and difficult to treat, secondary prevention in earlier stages
of drinking problems is virtually nonexistent, and many heavy
drinkers who are at risk of developing AUD in the future are not
targeted by health interventions.
In this article, we focus on the effective management of AUDs in
LMICs. We review the available evidence on the efficacy of treatments
and the delivery of interventions derived from LMICs. Because that
evidence is often limited, we also cite systematic reviews and meta-
analyses based on global evidence and key randomized controlled trials
(RCTs) from high income countries (HICs) where appropriate. On the
basis of our review, we propose a package of care—a combination of
treatments aimed at improving the recognition and management of
conditions to achieve optimal outcomes—for AUDs.
The Evidence on the Treatment of AUDs
Although there is now a substantial evidence base about the
relative effectiveness of different strategies for reducing the rates of
alcohol-related harm, most of the evidence derives from HICs and
cannot be transposed directly to LMIC settings. In Table 1, we
review the existing data and in this section, we discuss some
aspects of the evidence base in more detail.
Population-Level Interventions for Prevention
For populations with high rates of hazardous alcohol use, both
population-wide measures (for example, taxation on alcoholic
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physician advice) have been shown to have a notable impact on
reducing the global burden of alcohol misuse, although higher
rates of taxation may be ineffective in countries with undocu-
mented consumption. Other population-wide strategies, such as
reduced hours of sale and advertising bans, seem to have less
impact. For populations with low rates of hazardous drinking,
intervention strategies targeted at particular subgroups of the
drinking population, such as drivers who drink or primary-care
attendees with already high levels of alcohol consumption, appear
to be more cost effective than population-wide strategies like
taxation [12,22].
Early Detection and Brief Interventions for Early AUDs
The treatment gap in LMICs can be narrowed by broadening
the base of treatment and by opportunistic screening and brief
intervention (SBI) in primary health care settings. Several brief
screening instruments have been developed in HICs and one of
these—AUDIT (Alcohol Use Disorders Identification Test)—has
been shown to provide an accurate measure of risk across gender,
age, and cultures in several LMICs [23–29]. SBI provides a
framework for stepped intervention to help risky drinkers reduce
or stop alcohol consumption, which starts with simple but
structured advice, progresses to extended brief interventions, and
ends with referral to a specialist alcohol treatment service for those
with more serious problems and those who fail to respond to brief
interventions. Several reviews and meta-analyses of research
evidence collected in HICs in a variety of health care settings
and three RCTs in LMICs have concluded that SBI can effectively
reduce alcohol consumption to low-risk levels among hazardous
and harmful drinkers [30–39]. Other evidence from HICs suggests
that a combination of office support programs and education of
primary health care providers can increase the rate of screening
and advice giving of primary-health care providers [40]. Finally,
there is evidence from HICs that SBI can decrease alcohol-related
mortality for up to 16 y after the intervention [41].
Psychosocial Interventions to Prevent/Delay Relapse
These interventions fall into two main categories: structured
interventions and self-help groups. Two large US- and UK-based
RCTs that compared psychosocial therapies differing widely in
conceptual framework, intensity, duration, and location (Motivation
Enhancement Therapy [MET], Cognitive Behavior Therapy [CBT],
Twelve Step Facilitation [TSF] therapy, and Social Behavior and
Network Therapy [SBNT]) found minimal long-term difference
between inpatient/residential treatment and outpatient counseling
approaches [42,43]. These trials also found approximately equivalent
(and reasonably good) outcomes with both brief, nonintensive
treatments (MET) and intensive treatments (CBT, TSF, and SBNT)
for moderately severe alcoholics. A systematic review that considered
evidence collected in HICs concluded that manual-guided specific
treatments with a theoretical base (e.g., MET, CBT) are better than
nonspecific treatments (supportive therapy and social work interven-
tions), but that among the specific therapies none was superior [44].
The same review found that marital therapy and family intervention
yielded positive results. A meta-analysis of behavioral self-control
training found that this intervention reduced alcohol consumption and
Box 1. International Classification of Disease
10 Criteria for AUDs
Hazardous use [ICD 10; Z72.1]
‘‘A pattern of alcohol consumption that carries with it a risk
of harmful consequences to the drinker. These conse-
quences may be damage to physical or mental health, or
social consequences to the drinker or others. Other
potential consequences include worsening of existing
medical conditions or psychiatric illnesses, injuries caused
to self or others due to impaired judgment after drinking,
high risk sexual behaviors while intoxicated, and worsen-
ing of personal or social interactions’’. Hazardous use is
often operationalized as an average consumption of 21
drinks or more per week for men and 14 drinks or more
per week for women. It is recognized by the World Health
Organization (WHO) as a disorder distinct from other AUDs
[26].
Harmful use [ICD 10; F10.1]
‘‘A pattern of drinking that is already causing damage to
health. The damage may be either physical (e.g., liver
damage from chronic drinking) or mental (e.g., depressive
episodes secondary to drinking).
Harmful patterns of use are often criticized by others and
are sometimes associated with adverse social consequenc-
es of various kinds. However, the fact that a family or
culture disapproves of drinking is not by itself sufficient to
justify a diagnosis of harmful use’’ [9,26].
Alcohol dependence [ICD 10; F10.2]
‘‘A cluster of behavioural, cognitive, and physiological
phenomena that develop after repeated alcohol use and
that typically include a strong desire to take alcohol,
difficulties in controlling its use, persisting in its use
despite harmful consequences, a higher priority given to
alcohol use than to other activities and obligations,
increased tolerance, and sometimes a physical withdrawal
state’’ [9].
Summary Points
N Alcohol use disorders (AUDs)—conditions that range
from hazardous and harmful alcohol use to alcohol
dependence—are a low priority in low- and middle-
income countries (LMICs), despite causing a large health
burden.
N Most alcohol-related harm is attributable to hazardous/
harmful drinkers who make disproportionate use of
primary health care systems, but often go undetected
and untreated for long periods, even though brief, easily
delivered interventions are effective in this group of
people.
N Health care systems in LMICs currently focus on
providing tertiary care services for the treatment of
dependence (where there is often a poor outcome). This
focus needs to shift towards the cost-effective strategy
of providing brief interventions for early AUDs.
N Effective evidence-based combinations of psychosocial
and pharmacological treatments for AUDs are available
in LMICs but are costly to implement. Policy makers need
to ensure that people with AUDs are offered the most
appropriate services using stepped-care solutions that
start with simple, structured advice for risky drinkers and
progress to specialist treatment services for more serious
AUDs.
N LMICs also need to improve their implementation of
proven population-level preventive measures to reduce
the health burden due to AUDs. An international
Framework Convention on Alcohol Control may help
them do this.
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psychosocial interventions in LMICs, but one RCT in dependent
drinkers in Korea found that culturally modified cognitive behavioral
therapy increased the drinkers’ insight into their condition [46].
A Cochrane review of studies investigating the effectiveness of
strategies adopted by Alcoholics Anonymous and other self-help
groups to reduce alcohol dependence provided no definitive
evidence that these approaches are effective in HICs; there are no
data from LMICs about the effectiveness of self-help groups [47].
Pharmacotherapy for Detoxification and Relapse
Prevention
Conventionally, pharmacotherapy involves the use of benzodi-
azepines for detoxification and disulfiram for relapse prevention. A
systematic review from HICs showed that benzodiazepines remain
the agents of choice for treating alcohol withdrawal during
detoxification [48]. A recent RCT from India that compared
lorazepam and chlordiazepoxide found that these benzodiazepines
had comparable attenuating effects on uncomplicated withdrawal
[49]. Thus, lorazepam can be used in LMIC settings where it is
difficult to test liver function status, an essential preamble to using
long-acting benzodiazepines in patients.
A multisite RCT from the US concluded that the aversive agent
disulfiram might help prevent relapse in compliant patients but is
ineffective at promoting continuous abstinence [50]. Outcomes
were improved, however, if a supportive family member was able
to monitor compliance. RCTs undertaken in LMICs where
disulfiram is still the most commonly used medication for AUDs
because it is cheap and easily available show that it continues to be
a useful treatment particularly when compliance with the drug
regimen is overseen by family members [51].
A recent systematic review of data from HICs provides
substantial evidence that newer agents such as naltrexone,
acamprosate, topiramate, and baclofen have modest effects on
improving most outcome indicators (abstinent days, heavy drinking
days, days to lapse/relapse, and work and social functioning) in
alcohol-dependent individuals, although they do not guarantee
abstinence. Furthermore, when accompanied by brief advice, these
agents have been shown to improve overall outcome [52]. Although
these newer agents are relatively costly (which limits their use in
LMICs), they nevertheless offer a paradigm shift in the treatment of
AUDs. Treatment with these agents can be initiated while an
individual isstill drinkingheavilyand at thepoint of maximumcrisis
and help-seeking. They can also be safely delivered in general
practice and many other health care settings (unlike the scheduled
drug disulfiram, which, because of its toxicity and propensity to
cause severe reactions with alcohol, had to be strictly monitored and
could only be prescribed by addiction specialists), thus broadening
access to treatment. Although abstinence remains the ultimate goal
in treating alcohol-dependent individuals, reducing the frequency of
heavy drinking has the major impact of decreasing alcohol-related
consequences and improving quality of life. These agents may also
support effective treatment of hazardous/harmful alcohol use in
primary health care settings [53].
Two systematic reviews and several RCTs that have investigat-
ed the use of the opiate antagonist naltrexone for preventing
relapse in both HICs [54–57] and LMICs [58,59] have suggested
that this drug reduces the risk of relapse among recently abstinent,
alcohol-dependent individuals, though the effect-size is small. The
efficacy of naltrexone is greatest in people with high compliance,
in those reporting high levels of craving, and in those with a family
history of AUDs [60,61].
Table 1. Evidence in support of treatments for AUDs.
Intervention Evidence from HIC Evidence from LMIC
Early detection/screening Systematic reviews and RCTs of screening tools (AUDIT, CAGE, and
RAPS4) for alcohol problems in primary health care and other health
care settings [23–26]
Validation of AUDIT in LMICs [27–29]
Brief intervention Meta-analyses of brief interventions [30–36] RCTs of brief interventions in Brazil, India, and
Taiwan [37–39]
Systematic review of effects of a combination of educational and
office support programs on rates of screening and advice giving by
primary health care providers [40]
—
Psychosocial therapies for relapse prevention
Structured interventions Meta-analyses and systematic reviews of structured interventions
[42–45]
RCT of culturally modified cognitive behavioral
treatment in dependent drinkers in Korea [46]
Alcoholics Anonymous and other
self-help groups
Cochrane review of Alcoholics Anonymous and Twelve Step Facilitation
approaches for reducing alcohol dependence or problems [47]
—
Pharmacotherapy in detoxification and relapse prevention
Benzodiazepines Cochrane review of benzodiazepines for alcohol withdrawal [48] RCT comparing of lorazepam and chlordiazepoxide
for alcohol withdrawal in India [49]
Disulfiram Multisite RCT in the US [50]; RCT in Finland [94] RCT in India [69]
Naltrexone (opiate antagonist) Meta-analyses, a Cochrane review, and several RCTS of oral
naltrexone and intramuscular depot forms of naltrexone [53–57,60]
RCT in Taiwanese Han males [58]; RCT in Iran [59]
Acamprosate (glutamate inhibitor) Three meta-analyses [62,63,66]; two large RCTs including the US
COMBINE trial [59,64]
Multicenter RCT in combination with out-patient
psychosocial intervention in Korean alcohol-
dependent patients [65]
Topiramate (glutamate antagonist Two RCTs [67,68] RCT comparing disulfiram and topiramate in
patients with alcohol dependence in India [69]
Baclofen (GABA receptor agonist) Two RCTs investigating baclofen for maintenance of abstinence
and its safety patients with liver cirrhosis [70,71]
—
doi:10.1371/journal.pmed.1000170.t001
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acamprosate reported an increased percentage of nonheavy
drinking days and increased continuous abstinence rates at 6 mo
when compared to placebo but the effect sizes were small [62–64].
However, both the multisite US COMBINE trial [57] and an
RCT of acamprosate combined with out-patient psychosocial
intervention in Korean alcohol-dependent individuals [65] failed
to find any therapeutic benefit for this agent. A meta-analysis of
studies that compared the efficacy profiles of naltrexone and
acamprosate concluded that acamprosate was likely to be more
effective in preventing a lapse, whereas naltrexone more effectively
prevented a lapse becoming a relapse [66].
Table 1 also provides details of RCTs that have examined the
effect of the glutamate receptor antagonist topiramate (in HICs and
in India) on abstinence, relapse, and other alcohol-related outcomes
[67–69] and two RCTs that haveexamined the effect of the GABA-
B receptor agonist baclofen on drinking outcomes in HICs [70,71].
Delivery of Effective Interventions
Despite accruing evidence that medications may support
effective treatment of AUDs, treatment systems in LMICs by
and large continue to be dominated by psychosocial or religious
models and self-help groups that generally disavow biomedical
interventions [72,73]. There is also often limited availability of
these drugs in developing countries, their prices are high in the
open market, and public-health systems do not supply or subsidize
these medications. This last barrier to drug treatment for AUDs in
LMICs is not surprising given the unacceptably low spending on
health in these countries [74]. Furthermore health insurance is not
readily accessible in LMICs, and even if it were present, AUDs are
rarely covered by health insurance [75]. In Table 2, we propose a
series of steps that might be taken to improve the delivery of care
for AUDs in LMICs and in the rest of this section we provide a
brief discussion of some of these steps.
Interventions to Increase Consumer Demand and
Awareness
The social stigma attached to AUDs, the lack of knowledge
about available treatments, and poor sensitization among primary
health care providers delays treatment seeking by people with
early AUDs. In turn, because of the poor outcome of advanced
AUDs with conventional treatments, some health care profession-
als believe there is little point in trying to treat people with alcohol
problems (therapeutic nihilism). These factors contribute to the
large treatment gap in LMICs, and the low demand for services,
coupled with the perceived economic ‘‘benefits’’ from alcohol-
taxes, fuels official apathy towards upgrading services for the
treatment of AUDs [15]. To increase consumer demand and
awareness in order to get governments and planners to re-examine
the status quo, stakeholders in LMICs should pro-actively
disseminate the accruing evidence about the economic and social
costs of alcohol misuse in their country. They should also educate
their populations about the new understanding of AUDs as a
treatable brain disorder and about the availability of effective
treatments and use the media to influence the public discourse and
to sensitize policy makers and medical professionals [73].
Interventions to Increase Access to Treatment
In LMICs, detoxification and medical treatment of mild-to-
moderate alcohol withdrawal states can be safely managed in out-
patient or ambulatory settings under the supervision of community
nurses with medical support from local medical practitioners [76–80].
Furthermore, there is evidence that a ‘‘camp approach’’ in which
patients with substance dependence are treated in brief residential
Table 2. Delivering treatments for AUDs.
Step How By Whom In What Settings
Increasing consumer demand
and awareness
Reduce public stigma; Reduce therapeutic
nihilism in health care professionals; Influence
policy makers and public opinion; Establish an
international alcohol policy initiative.
Addiction medicine specialists,
mental health professionals, media
personnel; WHO and its member
states [93]
Community, primary health care,
specialist care
Reducing the impact of
hazardous drinking
Implement population level preventive
strategies using multisectoral approaches [22]
Taxation and civil administrative
authorities; Police; Mental health
professionals
Community, civil society
Increasing access and
recognition
Target early problems; Opportunistic screening;
Community treatment camps; Integration with
other noncommunicable disease delivery systems
Primary health care; Medical
specialists Community nurses;
Community health workers [76–78]
Clinics, hospitals, emergency
rooms, community
Increasing capacity/reducing
costs/improving efficiency
Training in SBI [85,86]; Training in manual-based
psychosocial interventions [90,91]
Addiction medicine specialists;
Mental health specialists
Specialized de-addiction centers,
psychiatry, psychology or social
work departments
Initiating evidence-based
treatments
Stepped-care approach [40,83] Primary health care personnel,
other medical specialties, specialized
addiction treatment providers
Clinics, hospitals, emergency
rooms; Community-based
treatment camps
Managing serious cases Referral to specialist treatment centers Addiction medicine specialists,
psychiatrists and other mental-health
professionals
Specialized de-addiction centers,
psychiatry wards of general
hospitals, rehabilitation centers.
Achieving optimal recovery/
outcome
Follow up in the community; early referral
on relapse
Community health workers, self-help
groups (Alcoholics Anonymous)
Primary health care clinics,
Alcoholics Anonymous meetings;
community
Addressing impacts of the
disorder on other health and
social outcomes
Integration with other noncommunicable disease
delivery systems (screening for risk factors),
integration with general mental-health delivery
systems
Other medical specialists;
mental-health specialists; policy
planners
Primary health and specialist
medical settings, community
health camps
doi:10.1371/journal.pmed.1000170.t002
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compared to inpatient hospital treatment [81]. Patient access to
treatment can also be greatly expanded by combining brief,
standardized behavioral treatments with the newer medications.
Such combinations improve overall outcome and can be delivered in
general practice and other primary health care settings. Importantly,
patients with chronic illnesses like AUDs benefit from the continuity
of care that primary health care professionals located in the patients’
community can provide—heavy drinking and alcohol addiction
severity are lower in patient cohorts who receive primary care [82].
Interventions to Increase the Availability, Reduce the
Costs, and Improve the Efficiency of Treatment
A greater proportion of AUDs could be effectively managed with the
existing, limited health care resources available in LMICs by
incorporating SBI within the normal clinical routine of primary health
care doctors and nurses [77]. These practitioners would need to be
trained to identify and stage AUDs and to provide a heuristic stepped-
care framework of intervention [83]. SBI, which is acceptable to both
patients and practitioners, is low-cost and is easily administered by
medically trained clinicians with minimal training in AUD treatments
[84]. Currently available training methods and manuals for SBI have
already been successfully used in LMICs [85,86].
Integration of interventions for AUDs within existing delivery
systems for the care of other noncommunicable diseases would
allow effective use of sparse resources. But, since primary health
care personnel burdened with multiple responsibilities are often
loath to take on additional tasks, AUD treatment services need to
be reconceptualised, not as standalone programs, but as part of
risk management strategies for other noncommunicable diseases—
alcohol misuse constitutes a prominent risk factor for a wide range
of noncommunicable diseases. Community level interventions
organized in the workplace and by nongovernmental organiza-
tions (NGOs) working in areas of development and microfinance
also merit further examination [87].
In most LMICs, NGOs and religious/social organizations (mostly
unregulated) provide help for AUDs that is often not evidence based
and is sometimes even inhumane [88]. The introduction of
regulations to ensure minimum standards of care will be difficult
because 25%–50% of LMICs do not have a national policy on
treatment of AUDs, but should nevertheless be attempted [89].
Several manual-based training schemes that cover psychosocial
interventions are freely available on the Internet, but more Web-
based resources need to be created and used to increase the
availability of treatment for AUDs [90,91]. Finally, national
addiction resource centers where available should be tasked with
training, certification, and monitoring, and encouraged to engage
in private-public partnerships with available treatment providers.
Packages of Care for AUDs in LMICs
Although our reviewsuggeststhat effectivemeasuresfor combating
AUDs exist in LMICs, a degree of scaling down when prescribing
care packages for LMIC settings is necessary to reflect the resource
availability on the ground. In Table 3 we compare possible packages
of care for AUDs in low- and high-resource countries.
More specifically, on the basis of our review, we propose that the
situation in LMICs calls for the adoption of a heuristic stepped-care
framework to match the needs of people with AUDs to the most
appropriate services. Each step in this framework represents an
increased complexity of intervention: (1) step 1 is recognition of
alcohol-related problems in primary health care and general
hospital settings; (2) step 2 is treatment of hazardous/harmful
drinking in primary care; (3) step 3 is treatment of moderate-to-
severe dependence in primary health care settings with referrals to
specialized units for relapse prevention; (4) step 4 is treatment by
mental-health or addiction specialists; (5) step 5 is inpatient
treatment. This stepped-framework approach has been used
successfully in the treatment of several mental-health problems,
notably depression[92], butas yetthere arefew well-studied models
of the approach in the field of substance abuse treatment.
However, it is important to remember that focussing on
treatment alone will not reduce the huge burden of disease caused
by alcohol in LMICs. Measures that target the drinking
environment and the general population in these countries also
need to be urgently implemented.
Finally, because the implementation of any of these packages of
care or of any other measures to reduce the burden of alcohol-
related disease cannot happen in LMICs without the active
participation of their governments and of nongovernmental
agencies, we strongly support the need for an international health
policy initiative in the form of a Framework Convention on Alcohol
Control, similar to that launched by the WHO for tobacco [93].
Author Contributions
ICMJE criteria for authorship read and met: VB PKC ISO. Wrote the first
draft of the paper: VB PKC. Contributed to the writing of the paper: VB
PKC ISO.
References
1. Beaglehole R, Bonita R (2009) Alcohol: a global health priority. Lancet 373:
2173–2174.
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y,
et al. (2009) Global burden of disease and injury and economic cost
attributable to alcohol use and alcohol-use disorders. Lancet 373: 2223–
2233.
3. Gururaj G, Benegal V, Girish N, Chandra V, Pandav R (2006) Alcohol control series
2: public health problems caused by harmful use of alcohol - gaining less or losing
more? New Delhi: World Health Organization, Regional Office for South East Asia.
4. Bonu S, Rani M, Peters DH, Jha P, Nguyen SN (2005) Does use of tobacco or
alcohol contribute to impoverishment from hospitalization costs in India? Health
Policy Plan 20: 41–49.
Table 3. Packages of care for AUDs.
Low Resourced Settings High Resourced Settings
Opportunistic screening Opportunistic screening
Stepped-care model, starting with
brief advice and working up to
extended brief interventions
Stepped-care model, starting with
brief advice and working up to
extended brief interventions
Community-based treatment of
withdrawal (detoxification)
Treatment of withdrawal in
community-based or specialized
de-addiction/rehabilitation centers
Structured relapse prevention in
self-help groups
Structured relapse prevention in self-
help groups; specialized interventions
including family based interventions
Pharmacotherapy with disulfiram
where family monitoring is available
and with newer medications where
available/affordable
Pharmacotherapy with newer
medications
Follow up and monitoring in the
community
Follow up and monitoring in the
community Follow up and monitoring
in specialized centers
Preventive interventions Preventive interventions
doi:10.1371/journal.pmed.1000170.t003
PLoS Medicine | www.plosmedicine.org 5 October 2009 | Volume 6 | Issue 10 | e10001705. Room R, Babor T, Rehm J (2005) Alcohol and public health. Lancet 365:
519–530.
6. Obot IS (2006) Alcohol use and related problems in sub-Saharan Africa. African
Journal of Drug and Alcohol Studies 5: 17–26.
7. BenegalV,NayakM,MurthyP,ChandraP,GururajG(2005)Women andalcohol
in India. Alcohol, gender and drinking problems: perspectives from low and middle
income countries. Obot IS, Room R, eds. pp 89–124. Geneva: World Health
Organisation. Available: http://www.who.int/substance_abuse/publications/
alcohol_gender_drinking_ problems. pdf]. Accessed on 9 September 2009.
8. Saunders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M (1993)
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO
Collaborative Project on Early Detection of Persons with Harmful Alcohol
Consumption-II. Addiction 88: 791–804.
9. World Health Organization (1992) The ICD-10 Classification of Mental and
Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
Geneva: World Health Organization.
10. Rehm J, Rehn N, Room R, Monteiro M, Gmel G, et al. (2003) The global
distribution of average volume of alcohol consumption and patterns of drinking.
Europ Addict Res 9: 147–156.
11. Gururaj G, Girish N, Benegal V (2006) Alcohol Control Series 1: Burden and
Socio-Economic Impact of Alcohol - The Bangalore Study. New Delhi: World
health Organisation, Regional Office for South East Asia, ISBN 92 9022 2727.
12. Anderson P (1991) Alcohol as a key area. BMJ 303: 766–769.
13. Babor T, Stenius K, Romelsjo A (2008) Alcohol and drug treatment systems in
public health perspective: mediators and moderators of population effects.
Int J Methods Psychiatr Res 17: S50–S59.
14. Perngparn U, Assanangkornchai S, Pilley C, Aramrattana A (2008) Drug and
alcohol services in middle-income countries. Curr Opin Psychiatry 21: 229–233.
15. Benegal V (2005) India: alcohol and public health. Addiction 100: 1051–1056.
16. Parry CDH (2005) Substance abuse intervention in South Africa. World
Psychiatry 4: 34–35.
17. Ray R (2004) Substance abuse and the growth of de-addiction centres: the
challenge of our times. Agarwal SP, ed. Mental health: an Indian perspective,
1946–2003. pp 284–289. New Delhi: Elsevier.
18. Kohn R, Saxena S, Levav I, Saraceno B (2004) The treatment gap in mental health
care. Bull World Health Organ 82: 858–866. Available: http://www.scielosp.org/
scielo.php?script=sci_arttext&pid=S0042-96862004001100011&lng=en. Accessed
9 September 2009.
19. Peltzer K, Matseke G, Azwihangwisi M, Babor T (2008) Evaluation of alcohol
screening and brief intervention in routine practice of primary care nurses in
Vhembe District, South Africa. Croat Med J 49: 392–401.
20. Lotrakul M, Saipanish R (2006) Psychiatric services in primary care settings: a
survey of general practitioners in Thailand. BMC Fam Pract 7: 48.
21. Benegal V, Gururaj G, Murthy P (2002) Project report on a WHO multi centre
collaborative project: on establishing and monitoring alcohol’s involvement in
casualties; 2000–2001 [monograph on the Internet]. Available: http://www.
nimhans.kar.nic.in/Deaddiction/lit/Alcohol%20and%20%20Injuries_
WHO%20Collab.pdf. Accessed 9 September 2009.
22. Chisholm D, Rehm J, Van Ommeren M, Monteiro M (2004) Reducing the
global burden of hazardous alcohol use: a comparative cost-effectiveness
analysis. J Stud Alcohol 65: 782–793.
23. Ewing John A (1984) Detecting alcoholism: the CAGE questionnaire. JAMA
252: 1905–1907.
24. Patton R, Crawford M, Touquet R (2004) Hazardous drinkers in the accident
and emergency department: who accepts advice? Emerg Med J 21: 491–492.
25. Borges A, Cherpitel CJ (2001) Selection of screening items for alcohol abuse and
alcohol dependence among Mexicans and Mexican Americans in the emergency
department. J Stud Alcohol 62: 277–285.
26. Saunders J, Aasland O, Babor T, de la Fuente J, Grant M (1993) Development
of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative
Project on Early Detection of Persons with Harmful Alcohol Consumption – II.
Addiction 88: 791–804.
27. Giang KB, Spak F, Dzung TV, Allebeck P (2005) The use of audit to assess level
of alcohol problems in rural Vietnam. Alcohol Alcohol 40: 578–583.
28. Lima CT, Freire AC, Silva AP, Teixeira RM, Farrell M, et al. (2005)
Concurrent and construct validity of the audit in an urban Brazilian sample.
Alcohol Alcohol 40: 584–589.
29. Adewuya AO (2005) Validation of the alcohol use disorders identification test
(audit) as a screening tool for alcohol-related problems among Nigerian
university students. Alcohol Alcohol 40: 575–577.
30. Kaner EFS, Dickinson HO, Beyer F, Pienaar E, Campbell F, et al. (2007)
Effectiveness of brief alcohol interventions in primary care populations.
Cochrane Database Syst Rev 18: CD004148.
31. Bertholet N, Daeppen J-B, Wietlisbach V, Fleming M, Burnand B (2005)
Reduction of alcohol consumption by brief alcohol intervention in primary care.
Arch Intern Med 165: 986–995.
32. Ballesteros J, Duffy JC, Querejeta I, Arino J, Gonzalez-Pinto A (2004) Efficacy of
brief interventions for hazardous drinkers in primary care: systematic review and
meta-analyses. Alcohol Clin Exp Res 28: 608–618.
33. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J (2004) Behavioral
counselling interventions in primary care to reduce risky/harmful alcohol use by
adults: a summary of the evidence for the US Preventive Services Task Force.
Ann Intern Med 140: 557–568.
34. Poikolainen K (1999) Effectiveness of brief interventions to reduce alcohol intake
in primary health care populations: a meta-analysis. Prev Med 28: 503–509.
35. Kahan M, Wilson L, Becker L (1995) Effectiveness of physician-based
interventions with problem drinkers: a review. Can Med Assoc J 152: 851–859.
36. Raistrick D, Heather N, Godfrey C (2006) Review of the effectiveness of treatment
for alcohol problems. London, National Treatment Agency for Substance Misuse,
Available: http://www.nta.nhs.uk/publications/documents/nta_review_of_the_
effectiveness_of_treatment_for_alcohol_problems_fullreport_2006_alcohol2.pdf.
Accessed 9 September 2009.
37. Sima ˜o MO, Kerr-Corre ˆa F, Smaira SI, Trinca LA, Floripes TM, et al. (2008)
Prevention of ‘‘risky’’ drinking among students at a Brazilian university. Alcohol
Alcohol 43: 470–476.
38. Pal HR, Yadav D, Mehta S, Mohan I (2007) A comparison of brief intervention
versus simple advice for alcohol use disorders in a North India community-based
sample followed for 3 months. Alcohol Alcohol 42: 328–332.
39. Tsai YF, Tsai MC, Lin YP, Chen CY (2009) Brief intervention for problem
drinkers in a Chinese population: a randomized controlled trial in a hospital
setting. Alcohol Clin Exp Res 33: 95–101.
40. Anderson P, Chisholm D, Fuhr DC (2009) Effectiveness and cost-effectiveness of
policies and programmes to reduce the harm caused by alcohol. Lancet 373:
2234–2246.
41. Kristenson H, Osterling A, Nilsson JA, Lindga ¨rde F (2002) Prevention of
alcohol-related deaths in middle-aged heavy drinkers. Alcohol Clin Exp Res 26:
478–484.
42. Babor TF, Del Boca FK, eds (2003) Treatment matching in alcoholism.
Cambridge: Cambridge University Press.
43. UKATT Research Team (2005) Effectiveness of treatment for alcohol problems:
findings of the randomised UK Alcohol Treatment Trial (UKATT). BMJ 311:
541–544.
44. Berglund M, Thelander S, Salaspuro M, Franck J, Andre ´asson S, et al. (2003)
Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Exp Res
27: 1645–1656.
45. Walters GD (2000) Behavioural self-control training for problem drinkers: a
meta-analysis of randomized control studies. Behav Ther 31: 135–149.
46. Im SB, Yoo EH, Kim JS, Kim GJ (2007) Adapting a cognitive behavioral
program in treating alcohol dependence in South Korea. Perspect Psychiatr
Care 43: 183–192.
47. Ferri MMF, Amato L, Davoli M (2006) Alcoholics Anonymous and other 12-
step programmes for alcohol dependence. Cochrane Database Syst Rev19:
CD005032.
48. Ntais C, Pakos E, Kyzas P, Ioannidis JPA (2005) Benzodiazepines for alcohol
withdrawal. Cochrane Database Syst Rev 3: CD005063.
49. Kumar CN, Andrade C, Murthy P (2009) A randomized, double-blind
comparison of lorazepam and chlordiazepoxide in patients with uncomplicated
alcohol withdrawal. J Stud Alcohol Drugs 70: 457–474.
50. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, et al. (1986)
Disulfiram treatment of alcoholism. A Veterans Administration cooperative
study. JAMA 256: 1449–1455.
51. Grover S, Basu D (2004) The revival (or, rather, survival) of disulfiram.
Addiction 99: 785.
52. Johnson BA (2008) Update on neuropharmacological treatments for alcoholism:
scientific basis and clinical findings. Biochem Pharmacol 75: 34–56.
53. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, et al. (2004)
Effectiveness of naltrexone in a community treatment program. Alcohol Clin
Exp Res 28: 1710–1717.
54. Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol
dependence. Cochrane Database Syst Rev 25: CD001867.
55. Bouza C, Angeles M, Munoz A, Amate JM (2004) Efficacy and safety of
naltrexone and acamprosate in the treatment of alcohol dependence: a
systematic review. Addiction 99: 811–828.
56. Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, et al.
(2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol
dependence: a randomized controlled trial. JAMA 293: 1617–1625.
57. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, et al. (2006)
Combined pharmaco-therapies and behavioral interventions for alcohol
dependence — The COMBINE Study: a randomized controlled trial. JAMA
295: 2003–2017.
58. Huang MC, Chen CH, Yu JM, Chen CC (2005) A double-blind, placebo-
controlled study of naltrexone in the treatment of alcohol dependence in
Taiwan. Addict Biol 10: 289–292.
59. Ahmadi J, Babaeebeigi M, Maany I, Porter J, Mohagheghzadeh M, et al. (2004)
Naltrexone for alcohol-dependent patients. Ir J Med Sci 173: 34–37.
60. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, et al. (1997)
Naltrexone and alcohol dependence: role of subject compliance. Arch Gen
Psychiatry 54: 737–742.
61. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley SS (2007) Family
history of alcoholism influences naltrexone-induced reduction in alcohol
drinking. Biol Psychiatry 62: 694–697.
62. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the
maintenance of abstinence in alcohol-dependent individuals: results of a meta-
analysis. Alcohol Clin Exp Res 28: 51–63.
63. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for
alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341.
PLoS Medicine | www.plosmedicine.org 6 October 2009 | Volume 6 | Issue 10 | e100017064. Chick J, Lehert P, Landron F. Plinius Maior Society (2003) Does acamprosate
improve reduction of drinking as well as aiding abstinence? J Psychopharmacol
17: 397–402.
65. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E (2003) Acamprosate in Korean
alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-
controlled study. Alcohol Alcohol 38: 135–141.
66. Rosner S, Leucht S, Lehert P, Soyka M (2008) Acamprosate supports
abstinence, Naltrexone prevents excessive drinking: evidence from a meta-
analysis with unreported outcomes. J Psychopharmacol 22: 11–23.
67. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, et al.
(2003) Oral topiramate for treatment of alcohol dependence: a randomised
controlled trial. Lancet 361: 1677–1685.
68. Ma JZ, Ait-Daoud N, Johnson BA (2006) Topiramate reduces the harm of
excessive drinking: implications for public health and primary care. Addiction
101: 1561–1568.
69. De Sousa AA, De Sousa J, Kapoor H (2008) An open randomized trial
comparing disulfiram and topiramate in the treatment of alcohol dependence.
J Subst Abuse Treat 34: 460–463.
70. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, et al. (2002)
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-
blind randomized controlled study. Alcohol Alcohol 37: 504–508.
71. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, et al. (2007)
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in
alcohol-dependent patients with liver cirrhosis: randomised, double-blind
controlled study. Lancet 370: 1915–1922.
72. Siqueira MM, Barbosa DA, Larajeira R, Hopkins K (2007) Psychoactive
substances and the provision of specialized care: the case of Espirito Santo. Rev
Bras Psiquiatr 29: 315–323.
73. Benegal V, Bajpai A, Basu D, Bohra N, Chatterji S, et al. (2007) Proposal to the
Indian Psychiatric Society for adopting a specialty section on addiction medicine
(alcohol and other substance abuse). Indian J Psychiatry 49: 277–282.
74. WHO (2001) WHO Report of the Commission on Macroeconomics and
Health. Geneva: World Health Organization.
75. Jutting J (2000) Social security systems in low-income countries: concepts,
constraints and the need for cooperation. International Social Security Review
53: 3–25.
76. Israel Y, Hollander O, Sanchez-Craig M, Booker S, Miller V, et al. (1996)
Screening for problem drinking and counseling by the primary care physician-
nurse team. Alcohol Clin Exp Res 20: 1443–1450.
77. Crawford M, Patton R, Touquet R, Drummond C, Byford S, et al. (2004)
Screening and referral for brief intervention of alcohol misusing patients in an
Accident and Emergency Department: a pragmatic randomised controlled trial.
Lancet 364: 1334–1339.
78. Hutchings D, Cassidy P, Dallolio E, Pearson P, Heather N, et al. (2006)
Implementing screening and brief alcohol interventions in primary care: views
from both sides of the desk. Primary Care Research and Development 7:
221–229.
79. Hayashida M, Alterman AI, McLellan AT, O’Brien CP, Purtill JJ, et al. (1989)
Comparative effectiveness and costs of inpatient and outpatient detoxification of
patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med
320: 358–365.
80. Stockwell T, Bolt L, Milner I, Pugh P, Young I (1990) Home detoxification for
problem drinkers: acceptability to clients, relatives, general practitioners and
outcome after 60 days. Br J Addict 85: 61–70.
81. Chavan BS, Gupta N, Arun LRP, Chanderbala (2003) Camp Approach - an
effective, alternate inpatient treatment setting for substance dependence: a report
from India. German J Psychiatry 6: 17–22.
82. Saitz R, Horton NJ, Larson MJ, Winter M, Samet JH (2005) Primary medical
care and reductions in addiction severity: a prospective cohort study. Addiction
100: 70–78.
83. Sobell MB, Sobell NC (2000) Stepped care as a heuristic approach to the
treatment of alcohol problems. J Consult Clin Psychol 68: 573–579.
84. Ernst DB, Pettinati HM, Weiss RD, Donovan DM, Longabaugh R (2008) An
intervention for treating alcohol dependence: relating elements of Medical
Management to patient outcomes with implications for primary care. Ann Fam
Med 6: 435–440.
85. Babor TF, Biddle-Higgins JC, Saunders JB, Monteiro MG (2001) AUDIT: The
Alcohol Use Disorders Identification Test: guidelines for use in primary health
care. Geneva: World Health Organization.
86. Babor T, Higgins-Biddle JC (2001) Brief intervention for hazardous and harmful
drinking: a manual for primary care. Geneva: World Health Organization.
87. Cercarelli R, Allsop S, Midford R, Pidd K (2009) Workplace interventions for
alcohol and other drug problems (Protocol). Cochrane Database Syst Rev. pp
CD007774.
88. TheHindu(Staff reporter)(2008)Rehabilitationcentresunderscanner.TheHindu.
Available: http://www.hindu.com/2008/11/13/stories/2008111359620300.htm.
Accessed 9 September 2009.
89. World Health Organization. Mental Health Atlas (2005) Available: http://www.
who.int/globalatlas/default.asp. Accessed 9 September 2009.
90. Miller WR, Zweben A, DiClemente CC, Rychtarik RG Motivational
Enhancement Therapy Manual. Washington (D.C.): National Institute on
Alcohol Abuse and Alcoholism. Project MATCH Monograph Series, volume 2.
Available: http://casaa.unm.edu/manuals/met.pdf. Accessed 9 September
2009.
91. Kadden R, Carroll K, Donovan D, Cooney N, Monti P, et al. (2004) Cognitive-
behavioral coping skills therapy manual: a clinical research guide for therapists
treating individuals with alcohol abuse and dependence. Washington (D.C.):
National Institute on Alcohol Abuse and Alcoholism, Project MATCH
Monograph Series, Volume 3, Available: http://pubs.niaaa.nih.gov/publica-
tions/MATCHSeries3/index.htm. Accessed 9 September 2009.
92. Patel V, Simon G, Chowdhary N, Kaaya S, Araya R (2009) Packages of care for
depression in low- and middle-income countries. PLoS Med 6: e159.
doi:10.1371/journal.pmed.1000159.
93. Casswell S, Thamarangsi T (2009) Reducing harm from alcohol: call to action.
Lancet 373: 2247–2257.
94. Laaksonen E, Koski-Ja ¨nnes A, Salaspuro M, Ahtinen H, Alho H (2008) A
randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone
and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 43:
53–61.
PLoS Medicine | www.plosmedicine.org 7 October 2009 | Volume 6 | Issue 10 | e1000170